Table 3.

NSC (AMID) counts for the NCI-60 tumor classes, derived by panel sensitivity

Tanimoto score
1.00.90.80.70.60.5
Leukemia3 (3)13 (7)25 (15)50 (23)103 (35)289 (63)
Lung2 (2)4 (3)9 (7)16 (13)42 (22)75 (35)
Colon3 (3)12 (7)32 (12)45 (18)88 (27)204 (47)
CNS5 (5)26 (8)57 (15)69 (20)104 (34)191 (50)
Melanoma1 (1)5 (4)7 (6)19 (11)55 (23)181 (45)
Ovarian1 (1)6 (4)15 (12)26 (18)54 (26)113 (45)
Renal2 (2)5 (5)18 (12)28 (14)55 (24)103 (44)
Prostate1 (1)9 (7)21 (11)32 (17)53 (29)93 (42)
Breast2 (2)5 (5)11 (8)17 (11)21 (13)42 (29)
Totals20 (20)85 (50)195 (98)302 (145)575 (233)1,291 (400)
Hit rate0.01 (0.05)0.65 (0.125)0.15 (0.25)0.23 (0.36)0.44 (0.58)1.0 (1.0)
  • NOTE: Number count for NSCs and, in parentheses, the count for their structurally similar AMIDs. As in Tables 1 and 2, the row “Totals” reflects cumulative counts based only on clinical trials having appropriate matches to the NCI-60 tumor panels. See the legend to Table 1 for more details.